Back
Alnylam Pharmaceuticals 10K Form
Sell
30
ALNY
Alnylam Pharmaceuticals
Last Price:
149.30
Seasonality Move:
19.79%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-02 | 10Q | ALNY/Alnylam Pharmaceuticals Quarterly |
| 2023-11-02 | 10Q | ALNY/Alnylam Pharmaceuticals Quarterly |
| 2023-08-03 | 10Q | ALNY/Alnylam Pharmaceuticals Quarterly |
| 2023-05-04 | 10Q | ALNY/Alnylam Pharmaceuticals Quarterly |
| 2022-10-27 | 10Q | ALNY/Alnylam Pharmaceuticals Quarterly |
| 2022-07-28 | 10Q | ALNY/Alnylam Pharmaceuticals Quarterly |
Receive ALNY News And Ratings
See the #1 stock for the next 7 days that we like better than ALNY
ALNY Financial Statistics
Sales & Book Value
| Annual Sales: | $1.83B |
|---|---|
| Cash Flow: | $-94.49M |
| Price / Cash Flow: | 148.37 |
| Annual Sales: | $-1.73 |
| Price / Book: | 0 |
Profitability
| EPS (TTM): | -2.68000 |
|---|---|
| Net Income (TTM): | $-332.08M |
| Gross Margin: | $1.52B |
| Return on Equity: | 0% |
| Return on Assets: | -9.08% |
Alnylam Pharmaceuticals Earnings Forecast
Key Alnylam Pharmaceuticals Financial Ratios
- The Gross Profit Margin over the past 19 years for ALNY is 83.02%.
- The Selling, General & Administrative Expenses for ALNY have been equal to 43.52% of Gross Profit Margin.
- The Research & Development expenses have been 54.94% of Revenue.
- The Interest Expense is -27.54% of Operating Income.
- The Net Earning history of ALNY is -24.08% of Total Revenues.
- Per Share Earnings over the last 22 years have been positive in 10 years.
Alnylam Pharmaceuticals Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | ALNY |
| CUSIP: | 02043Q |
| Website: | alnylam.com |
Debt
| Debt-to-Equity Ratio: | -4.66 |
|---|---|
| Current Ratio: | 3.17 |
| Quick Ratio: | 2.86 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
ALNY Technical Analysis vs Fundamental Analysis
Sell
30
Alnylam Pharmaceuticals (ALNY)
is a Sell
Is Alnylam Pharmaceuticals a Buy or a Sell?
-
Alnylam Pharmaceuticals stock is rated a Sell
The current Alnylam Pharmaceuticals [ALNY] share price is $149.40. The Score for ALNY is 30, which is 40% below its historic median score of 50, and infers higher risk than normal.